Screener
Royalty Pharma RPRX Total Revenue
Total Revenue at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income and other revenues | ||||
| Income from financial royalty assets | $638,027 | $550,418 | $1,233,019 | $1,089,908 |
| Other royalty income and revenues | 36,114 | 28,247 | 71,698 | 57,004 |
| Total income and other revenues | 674,141 | 578,665 | 1,304,717 | 1,146,912 |
| Operating expense/(income) | ||||
| Provision for changes in expected cash flows from financial royalty assets | 268,216 | (203,938) | 70,732 | (331,078) |
| Provision for credit losses on unfunded commitments | 13,068 | 92,535 | 9,368 | 92,535 |
| Research and development funding expense | 97,851 | 300,500 | 137,641 | 351,000 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's total revenue?
- Royalty Pharma (RPRX) reported total revenue of $674.14M in Q2 2026.
- How has Royalty Pharma's total revenue changed year-over-year?
- Royalty Pharma's total revenue increased by 16.5% year-over-year, from $578.67M to $674.14M.
- What is the long-term trend for Royalty Pharma's total revenue?
- Over 4 years (2021 to 2025), Royalty Pharma's total revenue has grown at a 1.0% compound annual growth rate (CAGR), from $2.29B to $2.38B.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Royalty Pharma's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude